🔴 Illumina is trading 5% down today as biotech stocks face pressure

Illumina is trading at $278.70, down 5.10%, as biotech stocks come under pressure.

• The XBI is down 2.50% during the regular session, offering sector context for Illumina’s decline.
• No clear company-specific news explaining the drop was identified. RBC’s October 5 price-target increase to $310 from $230 was a bullish prior-session catalyst, not an explanation for today’s decline.